** Shares of Invion rise as much as 130.6% to A$0.415, posting their biggest intraday percentage gain since Oct. 28, 2021
** Stock hits its highest level since July 16
** Cancer treatment developer says the first patient has been dosed in the early-stage trial of its light absorbing material "INV043", aimed to treat non-melanoma skin cancer
** About 483,000 shares change hands, compared with the 30-day average volume of around 37,000
** Stock trims YTD losses to 30%, including session's move
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.